flutamide has been researched along with Cardiovascular Diseases in 12 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 7.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 3.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| "Flutamide is a novel antiandrogen with fewer side effects." | 2.68 | Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. ( Blum, R; Chang, A; Davis, T; Fisher, H; Hahn, R; Khanna, O; Rosenthal, J; Schinella, R; Trump, D; Witte, R; Yeap, B, 1996) |
| "Elevated risks of arrhythmia (adjusted HR=1." | 1.46 | Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. ( Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X, 2017) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haque, R | 1 |
| UlcickasYood, M | 1 |
| Xu, X | 1 |
| Cassidy-Bushrow, AE | 1 |
| Tsai, HT | 1 |
| Keating, NL | 1 |
| Van Den Eeden, SK | 1 |
| Potosky, AL | 1 |
| Kupreeva, M | 1 |
| Diane, A | 1 |
| Lehner, R | 1 |
| Watts, R | 1 |
| Ghosh, M | 1 |
| Proctor, S | 1 |
| Vine, D | 1 |
| Voog, JC | 1 |
| Paulus, R | 1 |
| Shipley, WU | 2 |
| Smith, MR | 2 |
| McGowan, DG | 1 |
| Jones, CU | 1 |
| Bahary, JP | 1 |
| Zeitzer, KL | 1 |
| Souhami, L | 1 |
| Leibenhaut, MH | 1 |
| Rotman, M | 1 |
| Husain, SM | 1 |
| Gore, E | 1 |
| Raben, A | 1 |
| Chafe, S | 1 |
| Sandler, HM | 2 |
| Efstathiou, JA | 2 |
| Hedlund, PO | 3 |
| Johansson, R | 1 |
| Damber, JE | 2 |
| Hagerman, I | 2 |
| Henriksson, P | 3 |
| Iversen, P | 2 |
| Klarskov, P | 1 |
| Mogensen, P | 1 |
| Rasmussen, F | 2 |
| Varenhorst, E | 2 |
| Ala-Opas, M | 1 |
| Brekkan, E | 1 |
| Damber, L | 1 |
| Haukaas, S | 1 |
| Pousette, A | 1 |
| Salo, J | 1 |
| Vaage, S | 1 |
| Dockery, F | 1 |
| Bulpitt, CJ | 1 |
| Agarwal, S | 1 |
| Rajkumar, C | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Ajayi, AA | 1 |
| Halushka, PV | 1 |
| Bae, K | 1 |
| Hanks, GE | 1 |
| Pilepich, MV | 1 |
| Whelan, P | 1 |
| Chang, A | 1 |
| Yeap, B | 1 |
| Davis, T | 1 |
| Blum, R | 1 |
| Hahn, R | 1 |
| Khanna, O | 1 |
| Fisher, H | 1 |
| Rosenthal, J | 1 |
| Witte, R | 1 |
| Schinella, R | 1 |
| Trump, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Akkermansia Muciniphilia in Combating the Metabolic Effects of Androgen Deprivation Therapy in Men With Metastatic Prostate Cancer[NCT05802121] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE[NCT00767286] | Phase 3 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for flutamide and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Follow-Up Studies; Gosere | 2016 |
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial
Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Combined Modality Therapy; Estradiol | 2011 |
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Disease Progre | 2002 |
Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Arterie | 2002 |
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; | 2008 |
Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal | 1996 |
Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cardiovascular Di | 2000 |
5 other studies available for flutamide and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; Califor | 2017 |
Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
Topics: Androgen Antagonists; Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Blood G | 2019 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Castration reduces platelet thromboxane A2 receptor density and aggregability.
Topics: Aged; Androgen Antagonists; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Castrati | 2005 |
Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Topics: Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Goserelin; Humans; Male; Prosta | 2008 |